涩涩涩丁香色婷五月网,拍社区鲁交久久久伊人,深夜福利一区二区三区

貨號：A567818 同義名： PF-06650833

Zimlovisertib (PF-06650833)一種有效、選擇性且口服可利用的白介素-1 受體相關激酶 4 (IRAK4) 抑制劑，IC50 為 0.2 nM，在 PBMC 測試中的 IC50 為 2.4 nM，研究領域包括類風濕性關節炎、狼瘡和淋巴瘤。

Zimlovisertib 化學結構
CAS號：1817626-54-2

Zimlovisertib 3D分子結構
CAS號：1817626-54-2

規格	價格	會員價	庫存	數量
{[ item.pr_size ]} {[ size_append(item.pr_size_append, item.pr_am, item.pr_size) ]}

產品信息一鍵復制 購物車0 收藏詢單

產品信息一鍵復制復制成功
[email protected] [email protected] 400-920-2911 產品手冊產品訂購技術咨詢
快速發貨順豐冷鏈運輸，1-2 天到達

品質保證

技術支持

免費溶解

Zimlovisertib 純度/質量文件產品僅供科研

貨號：A567818 標準純度： {[allProObj[0].p_purity_real_show]} 產品說明書

批次查詢：批次純度: COA SDS NMR HPLC CNMR LC-MS

全球學術期刊中引用的產品: ? Nature, 2026. Ambeed. [ A111216 , A291101 , A169647 , A115820 , A113480 , A635338 , A139877 , A258659 ]; ? Adv. Mater., 2026, e11078. Ambeed. [ A1680754 ]; ? Adv. Mater., 2026, e17774. Ambeed. [ A551995 ]; ? Cell. Mol. Immunol., 2026. Ambeed. [ A145872 , A614767 , A136097 ]; ? ACS Nano, 2026, 20(2): 2200-2210. Ambeed. [ A232266 ]; 更多 >

Zimlovisertib 質控信息

Zimlovisertib 生物活性

Zimlovisertib 細胞實驗

Zimlovisertib 動物實驗

Zimlovisertib 參考文獻

Zimlovisertib 實驗方案

Zimlovisertib 技術信息

Cell Line Human peripheral blood mononuclear cells (hPBMC) T cells	Concentration	Treated Time	Description	References
Human peripheral blood mononuclear cells (hPBMC)	500 nmol/L	20 hours	To evaluate the effect of PF-06650833 on cytokine secretion after LPS stimulation. Results showed that PF-06650833 effectively reduced the secretion of inflammatory cytokines such as IL-1, IFN-γ, TNF-α, and IL-17.	Biomed Pharmacother. 2022 Sep;153:113459.
T cells	20 μM	96 hours	To evaluate the effect of PF-06650833 on T cell proliferation and IFN-γ production, results showed that PF-06650833 significantly suppressed IFN-γ production by T cells without affecting their proliferation.	Haematologica. 2020 Jan;105(1):226-234.

Species Mice Female Balb/c mice Mice HuNOG-EXL mice Balb/c mice	Animal Model Λ-carrageenan-induced paw edema and DSS-induced ulcerative colitis Inhaled lipopolysaccharide (LPS)-induced ARDS mouse model Graft-versus-host disease model CD34+ hematopoietic stem cell-engrafted NOG-EXL mice Inhaled LPS-induced ARDS mouse model	Administration	Dosage	Frequency	Description	References
Mice	Λ-carrageenan-induced paw edema and DSS-induced ulcerative colitis	Intravenous injection	23 mg/kg	Every other day for a total of four injections	To evaluate the accumulation and anti-inflammatory effects of VCAM1-targeted nanocarriers in inflamed tissues. Results demonstrated that VCAM1-targeted nanocarriers significantly reduced paw edema and colitis symptoms, decreased proinflammatory cytokine levels in affected tissues, and showed no apparent systemic toxicity.	Small. 2024 Jan;20(4):e2306270
Female Balb/c mice	Inhaled lipopolysaccharide (LPS)-induced ARDS mouse model	Oral	100 mg/kg	Preventive administration: one dose 30 min before modeling and another dose 6h after modeling; Therapeutic administration: two doses at 4 h and 12 h after modeling.	To evaluate the therapeutic effect of PF-06650833 in the ARDS model. Results showed that although PF-06650833 exhibited excellent IRAK4 inhibitory activity in vitro, it failed to significantly alleviate lung injury or reduce inflammatory cell infiltration in the in vivo model.	Biomed Pharmacother. 2022 Sep;153:113459.
Mice	Graft-versus-host disease model	Intravenous injection	12.0 mg/kg	Once daily for 20 days	To evaluate the effect of PF-06650833 on graft-versus-host disease, results showed that PF-06650833 significantly ameliorated morbidity and mortality of GvHD.	Haematologica. 2020 Jan;105(1):226-234.
HuNOG-EXL mice	CD34+ hematopoietic stem cell-engrafted NOG-EXL mice	Oral	100 mg/kg	Single dose, 30 minutes prior to challenge	Evaluate the inhibitory effect of PF-06650833 on AZ617-induced human TNFα, significantly reducing circulating human TNFα	J Biol Methods. 2023 Nov 20;10:jbm-10-e99010008
Balb/c mice	Inhaled LPS-induced ARDS mouse model	Oral	100 mg/kg	Preventive administration: single dose 30 min before modeling; Therapeutic administration: twice at 4 h and 12 h after LPS modeling	To evaluate the therapeutic effect of PF-06650833 in ARDS model. Results showed PF-06650833 failed to significantly improve lung injury scores and inflammatory cell infiltration, performing worse compared to BAY-1834845.	Biomed Pharmacother. 2022 Sep;153:113459

CAS號	1817626-54-2
分子式	C₁₈H₂₀FN₃O₄
分子量	361.37
SMILES Code	O=C(C1=CC2=C(C(OC[C@H]([C@H](CC)[C@@H]3F)NC3=O)=NC=C2)C=C1OC)N
MDL No.	MFCD30343869

別名	PF-06650833
運輸	藍冰
InChI Key	JKDGKIBAOAFRPJ-ZBINZKHDSA-N
Pubchem ID	118414016

存儲條件

In solvent -20°C: 3-6個月 -80°C: 12個月

Pure form Sealed in dry, 2-8°C

溶解方案

細胞實驗：

DMSO: 60 mg/mL(166.04 mM)，配合低頻超聲，并水浴加熱至45℃助溶，注意：DMSO長時間開封后，會吸水并導致溶解能力下降，請避免使用長期開封的DMSO

動物實驗：請根據您的動物給藥指南選擇適當的溶解方案。
以下溶解方案都請先按照體外實驗的方式配制澄清的儲備液，再依次添加助溶劑：
——為保證實驗結果的可靠性，澄清的儲備液可以根據儲存條件，適當保存；體內實驗的工作液，建議現用現配，當天使用；以下溶劑前顯示的百分比是指該溶劑在終溶液中的體積占比；如在配制過程中出現沉淀、析出現象，可以通過加熱和/或超聲的方式助溶

方案一

方案二

方案三

配制的工作液建議現用現配，短期內盡快用完。以下溶劑前顯示的百分比是指該溶劑在終溶液中的體積占比；如在配制過程中出現沉淀、析出現象，可以通過加熱和/或超聲的方式助溶。

方案一

Zimlovisertib {[allProObj[0].p_purity_real_show]}

Zimlovisertib 純度/質量文件產品僅供科研

全球學術期刊中引用的產品

Zimlovisertib 質控信息

Zimlovisertib 生物活性

Zimlovisertib 細胞實驗

Zimlovisertib 動物實驗

Zimlovisertib 參考文獻

Zimlovisertib 實驗方案

Zimlovisertib 技術信息

最近瀏覽的產品

大規格詢價

摩爾計算器

靶點

總藥量計算器

工作液計算器

細胞研究

臨床研究

確認信息

熱門區域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Zimlovisertib {[allProObj[0].p_purity_real_show]}

Zimlovisertib 純度/質量文件 產品僅供科研

全球學術期刊中引用的產品

Zimlovisertib 質控信息

Zimlovisertib 生物活性

Zimlovisertib 細胞實驗

Zimlovisertib 動物實驗

Zimlovisertib 參考文獻

Zimlovisertib 實驗方案

Zimlovisertib 技術信息

最近瀏覽的產品

大規格詢價

摩爾計算器

靶點

總藥量計算器

工作液計算器

細胞研究

臨床研究

確認信息

請登錄您的專屬賬戶

熱門區域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Zimlovisertib 純度/質量文件產品僅供科研